Business
GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024
About this update from Genedx Holdings Corp.
[{"type":"text","content":"\n\nReported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit)\n\n\n\nAccelerated exome and genome volume growth to 34% year-over-year\n\n\n\nReported fourth quarter 2025 adjusted gross margin1 of 71%\n\n\n\nReported fourth quarter 2025 adjusted net income1 of $4.4 million\n\n\n\nReaffirmed full year 2026 guidance of $540 to $555 million in revenue with 33-35% exome and genome growth\n\n\n\nGeneDx to host conference call today at 8:30 a.m. ET\n\n\n\n GAITHERSBURG, Md.--(BUSINESS WIRE)--\nGeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the fourth quarter and full year of 2025.\n\n\n“The unmet need for early, accurate genomic diagnosis is enormous, and families are waiting far too long for answers. GeneDx is uniquely positioned to deliver for patients, clinicians, and partners — and our results demonstrate that. Our team is executing at the highest level, our platform continues to scale, and GeneDx InfinityTM gives us a compounding data advantage that strengthens with every test we run,” said Katherine Stueland, President and CEO of GeneDx. “The business has never been in a better position for continued growth and success. As we enter 2026, we will layer new growth drivers onto an already powerful foundation — expanding into large, underpenetrated markets where patients are waiting for a diagnosis that GeneDx can provide today.”\n\n\nFourth Quarter and Full Year 2025 Financial Results (Unaudited)1,2\n\n\nRevenues\n\n\nFourth quarter 2025:\n\n\n\nRevenues grew to $121.0 million, an increase of 27% year-over-year (37% excluding a one-time 2024 benefit).\n\n\n\nExome and genome test revenue grew to $104.0 million, an increase of 32% year-over-year (42% excluding a one-time 2024 benefit).\n\n\n\nFull year 2025:\n\n\n\nRevenues grew to $427.5 million, an increase of 41% year-over-year (45% excluding a one-time 2024 benefit).\n\n\n\nExome and genome test revenue grew to $360.3 million, an increase of 54% year-over-year (58% excluding a one-time 2024 benefit).\n\n\n\nExome and genome volume\n\n\nFourth quarter 2025:\n\n\n\nExome and genome test result volume grew to 27,761, an increase of 34.3% year-over-year.\n\n\n\n...